Follow
Cytovac AB
Nasdaq First North Sweden (Sweden)
Cytovac is a growing Danish biotech company, which has chosen to focus on development of a cancer treatment that uses the body’s own immune system.
Sector:
HEALTH CARE
Current instruments
News
Nothing to display for this company
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
Nasdaq First North Sweden
Sweden (SE)
Details of share in Cytovac AB with ticker
Status
Active
Order book id
Amount of instruments
Par value
Market cap
Currency
SEK
Segment
First North Premier
Terms
Type
Price
Pre-money valuation
Time
Listing
-
2020
Direct listing of Cytovac AB on Nasdaq First North Sweden
Market
Nasdaq First North Sweden
Status
Upcoming
Comments for listing & related information
Cytovac plans to release an IPO prospectus at the end of April 2019, with a subscription period in May and listing at the end of May.

Update: The company started to market their IPO in April 2019 but cancelled, citing weak market conditions. The company will instead do a private investment round and do an IPO after a Phase II study is finished, which is expected in the summer of 2020.
People
Jan Kuhlmann Andersen
Chairman of the board
Peter Bonne Eriksen
Board member
Per Falholt
Board member
Lars Bjerrek
Board member
Fredrik Buch
Board member
Company Details
Sector
HEALTH CARE

Address
Box 7714
Zip code
103 95
City/district
Stockholm
Country
Sweden (SE)
Registration number
5591623318
LEI code
5493000U5K1HLJUSIW21
First trade date
Registration date
14 Jun 2018
Short name
Cytovac

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More